ATyr Accumulated Other Comprehensive Income from 2010 to 2024
| LIFE Stock | USD 1.73 0.03 1.70% |
Accumulated Other Comprehensive Income | First Reported 2010-03-31 | Previous Quarter -74 K | Current Value -158 K | Quarterly Volatility 1.4 B |
Check ATyr Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ATyr main balance sheet or income statement drivers, such as Interest Expense of 2 M, Selling General Administrative of 12.3 M or Total Revenue of 335.4 K, as well as many exotic indicators such as Price To Sales Ratio of 225, Dividend Yield of 0.0 or PTB Ratio of 0.79. ATyr financial statements analysis is a perfect complement when working with ATyr Pharma Valuation or Volatility modules.
ATyr | Accumulated Other Comprehensive Income |
Latest ATyr Pharma's Accumulated Other Comprehensive Income Growth Pattern
Below is the plot of the Accumulated Other Comprehensive Income of aTyr Pharma over the last few years. It is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. ATyr Pharma's Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ATyr Pharma's overall financial position and show how it may be relating to other accounts over time.
| Accumulated Other Comprehensive Income | 10 Years Trend |
|
Accumulated Other Comprehensive Income |
| Timeline |
ATyr Accumulated Other Comprehensive Income Regression Statistics
| Arithmetic Mean | 930,262,780 | |
| Geometric Mean | 1,314,933 | |
| Coefficient Of Variation | 207.14 | |
| Mean Deviation | 1,489,280,088 | |
| Median | (74,000) | |
| Standard Deviation | 1,926,939,371 | |
| Sample Variance | 3713095.3T | |
| Range | 4.7B | |
| R-Value | (0.69) | |
| Mean Square Error | 2071827.8T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (299,103,261) | |
| Total Sum of Squares | 51983334.7T |
ATyr Accumulated Other Comprehensive Income History
About ATyr Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ATyr Pharma income statement, its balance sheet, and the statement of cash flows. ATyr Pharma investors use historical funamental indicators, such as ATyr Pharma's Accumulated Other Comprehensive Income, to determine how well the company is positioned to perform in the future. Although ATyr Pharma investors may use each financial statement separately, they are all related. The changes in ATyr Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ATyr Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ATyr Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ATyr Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -74 K | -70.3 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether aTyr Pharma is a strong investment it is important to analyze ATyr Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ATyr Pharma's future performance. For an informed investment choice regarding ATyr Stock, refer to the following important reports:Check out the analysis of ATyr Pharma Correlation against competitors. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.Note that the aTyr Pharma information on this page should be used as a complementary analysis to other ATyr Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ATyr Stock analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is ATyr Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.29) | Return On Equity (0.56) |
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.